Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 117876
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.117876
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.117876
Figure 1 ASAP3 expression in gastric cancer, and cell transfection efficiency.
A: Relative expression of ASAP3 in gastric cancer (GC) cell lines (AGS and HGC-27 cells); B: Cell transfection efficiency assessed by determining the messenger RNA (mRNA) expression of ASAP3 in AGS transfected with over-expression-ASAP3 plasmids; C: Cell transfection efficiency assessed by determining the mRNA expression of ASAP3 in HGC-27 transfected with short hairpin-ASAP3 plasmids; D: Proliferation of GC cells (HGC-27 and AGS) after transfection using cell counting kit-8 after cultured for 24 hours, 48 hours, and 72 hours. aP < 0.05 vs AGS cell. bP < 0.05 vs HGC-27 cell. cP < 0.05 vs short hairpin-negative control-HGC-27 cell. dP < 0.05 vs over-expression-negative control-AGS cell. mRNA: Messenger RNA; oe: Over-expression; sh: Short hairpin; NC: Negative control.
- Citation: Huang XB, Deng Y, Gong SY, Yu M, Cai H. ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression. World J Gastrointest Oncol 2026; 18(8): 117876
- URL: https://www.wjgnet.com/1948-5204/full/v18/i8/117876.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i8.117876